EN HU

Ngo Minh Toan

Publication list

2025
1.
Ngo, M. T., Vágner, A., Nagy, G., Ország, G., Nagy, T., Szoboszlai, Z., Csikos, C., Váradi, B., Trencsényi, G., Tircsó, G., Garai, I.: HER2 expression in different cell lines at different inoculation sites assessed by [52Mn]Mn-DOTAGA(anhydride)-trastuzumab.
Pathol. Oncol. Res. 31, 1-12, (article identifier: 1611999), 2025.
Journal metrics:
Q3 Cancer Research (2024)
Q2 Medicine (miscellaneous) (2024)
Q2 Oncology (2024)
Q2 Pathology and Forensic Medicine (2024)
2.
Ngo, M. T., Nagy, T., Szoboszlai, Z., Csikos, C., Dénes, N., Furka, A., Trencsényi, G., Garai, I.: The Relationship of Metabolic Activity and αvβ3 Receptor Expression in Aggressive Breast Cancer Subtypes Tumors: a Preliminary Report.
In Vivo. 39 (1), 160-171, 2025.
Journal metrics:
Q2 Biochemistry, Genetics and Molecular Biology (miscellaneous) (2024)
Q3 Cancer Research (2024)
Q2 Medicine (miscellaneous) (2024)
Q3 Pharmacology (2024)
2024
3.
Ngo, M. T., Vágner, A., Nagy, G., Ország, G., Nagy, T. M., Csikos, C., Váradi, B., Sajtos, G. Z., Kapus, I., Szoboszlai, Z., Szikra, D. P., Trencsényi, G., Tircsó, G., Garai, I.: [52 Mn]Mn-BPPA-Trastuzumab: A Promising HER2-Specific PET Radiotracer.
J. Med. Chem. 67 (10), 8261-8270, 2024.
Journal metrics:
D1 Drug Discovery
Q1 Molecular Medicine
4.
Ngo, M. T.: Novel Molecular Classification of Breast Cancer with PET Imaging.
Medicina (Kaunas). 60 (12), 1-35, (article identifier: 2099), 2024.
Journal metrics:
Q2 Medicine (miscellaneous)
5.
Ngo, M. T., Lê, Á. N., Đinh, D. P. H.: The Impact of Chemotherapy on Cardiovascular Mortality across Breast Cancer Subtypes.
Current Oncology. 31 (2), 649-659, 2024.
Journal metrics:
Q2 Oncology
2023
6.
Csikos, C., Vágner, A., Nagy, G., Kálmán-Szabó, I., Péli-Szabó, J., Ngo, M. T., Szoboszlai, Z., Szikra, D. P., Krasznai, Z. T., Trencsényi, G., Garai, I.: In Vivo Preclinical Assessment of the VEGF Targeting Potential of the Newly Synthesized [52Mn]Mn-DOTAGA-Bevacizumab Using Experimental Cervix Carcinoma Mouse Model.
Diagnostics. 13 (2), 236-, 2023.
Journal metrics:
Q2 Clinical Biochemistry
7.
Váradi, B., Brezovcsik, K., Garda, Z., Madarasi, E., Szedlacsek, H., Badea, R. A., Vasilescu, A. M., Puiu, A. G., Ionescu, A. E., Sima, L. E., Munteanu, C. V. A., Cǎlǎraş, S., Vágner, A., Szikra, D. P., Ngo, M. T., Nagy, T., Szűcs, Z., Szedlacsek, S. E., Nagy, G., Tircsó, G.: Synthesis and characterization of a novel [52Mn]Mn-labelled affibody based radiotracer for HER2+ targeting.
Inorg. Chem. Front. 10 (16), 4734-4745, 2023.
Journal metrics:
D1 Inorganic Chemistry
2022
8.
Vágner, A., Ngo, M. T., Nagy, G., Nagy, T., Sajtos, G. Z., Váradi, B., Szikra, D. P., Tircsó, G., Garai, I.: In vivo imaging of HER2 receptor status with a novel Mn-52-labelled antibody.
Eur. J. Nucl. Med. Mol. Imaging. 49 (SUPPL1), S282-S282, 2022.
9.
Váradi, B., Garda, Z., Madarasi, E., Brezovcsik, K., Vágner, A., Nagy, T., Garai, I., Ngo, M. T., Puiu, A. G., Vasilescu, A. M., Szűcs, Z., Szedlacsek, S. E., Nagy, G., Tircsó, G.: Labelling anti-HER2-affibodies with Mn-52 via pyclen based bifunctional ligands: from ligand design to in vivo PET/MR experiments.
Eur. J. Nucl. Med. Mol. Imaging. 49 (SUPPL1), S283-S283, 2022.
DEENK University of Debrecen
© 2012 University of Debrecen